Skip to main content

Table 4 Efficacy results during VEM1-IPI

From: Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

  Result
Best overall response, n (%)  
 Complete response 2 (4.3)
 Partial response 13 (28.3)
 Stable disease 5 (10.9)
 Progressive disease 11 (23.9)
 Unknowna 15 (32.6)
Best overall response rate, % (95 % CI) 32.6 (19.5–48.0)
Median duration of response, mo (95 % CI) 23.1 (5.03–NE)
Median duration of stable disease, mo (95 % CI) 5.2 (3.98–14.75)
  1. CI confidence interval, IPI ipilimumab, mo month, NE not evaluable, VEM vemurafenib
  2. aResponse could not be determined due to missing assessment, image quality, etc